Expression of HBME-1,CK19 and Galectin-3 in papillary thyroid carcinoma and their diagnostic value
DOI:
CSTR:
Author:
Affiliation:

Clc Number:

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Objective:To investigate the usefulness of immunohistochemical expression and immunolocalization of a panel of papillary thyroid carcinoma markers including HBME-1,CK19 and Galectin-3. Methods:By immunochemical EnVision method, the expression of HBME-1,CK19 and Galectin-3 were detected in 55 cases of papillary thyroid carcinomas,24 follicular adenomas, 20 multinodular goiters and 10 Hashimoto’s thyroiditis. Results:The rates of immuno-positive staining of HBME-1,CK19 and Galectin-3 in papillary thyroid carcinoma were 96.4%,98.2% and 94.5%, respectively, which were significantly higher than that of benign lesions(20.4%, 20.4% and 22.2%, respectively). No significant relationship was found among the expressions of HBME-1, CK19 and Galectin-3. The sensibility, specificity,positive predictive value, negative predictive value and accuracy rate of using HBME-1 combined with CK19, Galectin-3 in differentiation benign from papillary thyroid carcinoma were 100%, 96.9%, 98.8%, 98%, 100% respectively. Conclusion:An immunohistochemical panel consisting of HBME-1, CK19 and Galectin-3 can make a correct differential diagnosis between papillary thyroid carcinoma and its benign mimics.

    Reference
    Related
    Cited by
Get Citation

黄 悦,赵建华,樊克武. HBME-1和CK19、Galectin-3在甲状腺乳头状癌中表达及诊断价值[J].南京医科大学学报(自然科学版英文版),2007,(11):1294-1297.

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:May 16,2007
  • Revised:
  • Adopted:
  • Online:
  • Published:
Article QR Code